



**Fig.S1. Mechanism of tumor suppression by 3M-052.** Tumor growth after 3M-052 treatment in (A) B16.F10 in CD8-depleted or WT mice (B) B16.Ova in CCL2 neutralized mice or WT mice. Tumor growth is plotted as mean  $\pm$  SEM, n=5 in each group. \*P<0.05, \*\*P<0.005 (unpaired two-tailed t test).

**A****B**

**Fig. S2. Synergistic effect of triple therapy and its mechanism of action.** Mice bearing 7-day and 3-day subcutaneous B16.F10 tumors on opposite flanks were treated only in the 7-day tumor on day 0 and 4 with 35ug 3M-052 or vehicle. i.t. and received 100 ug each of anti-CTLA-4 and anti-PD-L1 or IgG isotype control i.p. every 4 days. **(A)** Growth of uninjected, distant tumor is shown. **(B)** Survival of mice; with or without CD8 T cells depletion mean  $\pm$  SEM, n= 4 or 5. \*P<0.05, \*\*P<0.005.